Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review

키워드

참고문헌 (77)

1. Wong RJ, "Trends in liver disease etiology among adults awaiting liver transplantation in the United States, 2014-2019", JAMA Netw Open, 3, pp.e1920294~ (2020)
2. Bertot LC, "Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease", Expert Rev Gastroenterol Hepatol, 13, pp.179~187 (2019)
3. Jong Man Kim, "Outcomes after Liver Transplantation in Korea: Incidence and Risk Factors from Korean Transplantation Registry", Clinical and Molecular Hepatology, 27(3), pp.451~462 (2021), 대한간학회[DOI]
4. Lu TF, "Liver transplantation for hepatocellular carcinoma : recent advances in China", J Dig Dis, 15, pp.51~53 (2014)
5. Iwatsuki S, "Hepatic resection versus transplantation for hepatocellular carcinoma", Ann Surg, 214, pp.221~229 (1991)
6. Ringe B, "Surgical treatment of hepatocellular carcinoma : experience with liver resection and transplantation in 198 patients", World J Surg, 15, pp.270~285 (1991)
7. Mazzaferro V, "Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis", N Engl J Med, 334, pp.693~699 (1996)
8. Yao FY, "Liver transplantation for hepatocellular carcinoma : expansion of the tumor size limits does not adversely impact survival", Hepatology, 33, pp.1394~1403 (2001)
9. Toniutto P, "Risk factors for hepatocellular carcinoma recurrence after liver transplantation", Hepatoma Res, 6, pp.50~ (2020)
10. Lee S, "Diagnostic performance of CT", MRI liver imaging reporting and data system v2017 for hepatocellular carcinoma : a systematic review and meta-analysis, 2020, pp.40, 1488~1497
11. Toniutto P, "Liver transplantation in patients with hepatocellular carcinoma beyond the milan criteria : a comprehensive review", J Clin Med, 10, pp.3932~ (2021)
12. Shah SA, "Does microvascular invasion affect outcomes after liver transplantation for HCC? A histopathological analysis of 155consecutive explants", J Gastrointest Surg, 11, pp.464~471 (2007)
13. Mazzaferro V, "Milan criteria in liver transplantation for hepatocellular carcinoma : an evidence-based analysis of 15 years of experience", Liver Transpl (2011)
14. Mazzaferro V, "Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria : a retrospective, exploratory analysis", Lancet Oncol, 10, pp.35~43 (2009)
15. Sugawara Y, "Living donor liver transplantation for hepatocellular carcinoma : Tokyo University series", Dig Dis, 25, pp.310~312 (2007)
16. Lee SG, "Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center", Liver Transpl, 14, pp.935~945 (2008)
17. Duvoux C, "Liver transplantation for hepatocellular carcinoma : a model including α-fetoprotein improves the performance of Milan criteria", Gastroenterology, 143, pp.986~994 (2012)
18. Notarpaolo A, "Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC", J Hepatol, 66, pp.552~559 (2017)
19. Rhu J, "Validation of the α-fetoprotein model for hepatocellular carcinoma recurrence after transplantation in an Asian population", Transplantation, 102, pp.1316~1322 (2018)
20. Degroote H, "Extended criteria for liver transplantation in hepatocellular carcinoma. A retrospective, multicentric validation study in Belgium", Surg Oncol, 33, pp.231~238 (2020)
21. Piñero F, "Liver transplantation for hepatocellular carcinoma : evaluation of the alpha-fetoprotein model in a multicenter cohort from Latin America", Liver Int, 36, pp.1657~1667 (2016)
22. Mazzaferro V, "Metroticket 2. 0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma", Gastroenterology, 154, pp.128~139 (2018)
23. Kim JM, "Expanded criteria for liver transplantation in patients with hepatocellular carcinoma", Transplant Proc, 46, pp.726~729 (2014)
24. Shimamura T, "Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey : the 5-5-500 rule-a retrospective study", Transpl Int, 32, pp.356~368 (2019)
25. Okuda H, "Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein alone and those seropositive for des-gamma-carboxy prothrombin alone", J Gastroenterol Hepatol, 16, pp.1290~1296 (2001)
26. Poté N, "Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion", J Hepatol, 62, pp.848~854 (2015)
27. Taketomi A, "Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation", Transplantation, 87, pp.531~537 (2009)
28. Takada Y, "Liver transplantation for hepatocellular carcinoma : the Kyoto experience", J Hepatobiliary Pancreat Sci, 17, pp.527~532 (2010)
29. Lee JH, "Serum tumor markers provide refined prognostication in selecting liver transplantation candidate for hepatocellular carcinoma patients beyond the Milan criteria", Ann Surg, 263, pp.842~850 (2016)
30. Cillo U, "Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma", Ann Surg, 239, pp.150~159 (2004)
31. DuBay D, "Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion", Ann Surg, 253, pp.166~172 (2011)
32. Silva MA, "Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer : a systematic review and meta-analysis", Gut, 57, pp.1592~1596 (2008)
33. Sparchez Z, "Contemporary role of liver biopsy in hepatocellular carcinoma", World J Hepatol, 10, pp.452~461 (2018)
34. Al-Ameri AAM, "Systematic review : risk prediction models for recurrence of hepatocellular carcinoma after liver transplantation", Transpl Int, 33, pp.697~712 (2020)
35. Mehta N, "Validation of a risk estimation of tumor recurrence after transplant(RETREAT)score for hepatocellular carcinoma recurrence after liver transplant", JAMA Oncol, 3, pp.493~500 (2017)
36. Halazun KJ, "Recurrence after liver transplantation for hepatocellular carcinoma : a new MORAL to the story", Ann Surg, 265, pp.557~564 (2017)
37. Goldberg D, "Predicting survival after liver transplantation in patients with hepatocellular carcinoma using the LiTES-HCC score", J Hepatol, 74, pp.1398~1406 (2021)
38. Oh D, "Early three-dimensional conformal radiotherapy for patients with unresectable hepatocellular carcinoma after incomplete transcatheter arterial chemoembolization : a prospective evaluation of efficacy and toxicity", Am J Clin Oncol, 33, pp.370~375 (2010)
39. Silva JP, "Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis", HPB(Oxford), 19, pp.659~666 (2017)
40. Ravaioli M, "Liver transplantation for hepatocellular carcinoma : results of down-staging in patients initially outside the Milan selection criteria", Am J Transplant, 8, pp.2547~2557 (2008)
41. Mehta N, "Excellent outcomes of liver transplantation following down-staging of hepatocellular carcinoma to within Milan criteria : a multicenter study", Clin Gastroenterol Hepatol, 16, pp.955~964 (2018)
42. Yao FY, "Downstaging of hepatocellular cancer before liver transplant : long-term outcome compared to tumors within Milan criteria", Hepatology, 61, pp.1968~1977 (2015)
43. Lencioni R, "Modified RECIST(mRECIST)assessment for hepatocellular carcinoma", Semin Liver Dis, 30, pp.52~60 (2010)
44. Lai Q, "Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation", Liver Transpl, 19, pp.1108~1118 (2013)
45. Halazun KJ, "Standing the test of time : outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment", Hepatology, 60, pp.1957~1962 (2014)
46. Heimbach JK, "AASLD guidelines for the treatment of hepatocellular carcinoma", Hepatology, 67, pp.358~380 (2018)
47. European Association for the Study of the Liver, "EASL clinical practice guidelines : management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
48. Lai Q, "A novel prognostic index in patients with hepatocellular cancer waiting for liver transplantation : time-radiologicalresponse-alpha-fetoprotein-inflammation(TRAIN)score", Ann Surg, 264, pp.787~796 (2016)
49. Mazzaferro V, "Liver transplantation in hepatocellular carcinoma after tumour downstaging(XXL) : a randomised, controlled, phase 2b", 3 trial, 2020, pp.21, 947~956
50. 김상진, "Liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis", Journal of Liver Cancer, 21(2), pp.105~112 (2021), 대한간암학회
51. Ioannou GN, "Assessment of a deep learning model to predict hepatocellular carcinoma in patients with hepatitis C cirrhosis", JAMA Netw Open, 3, pp.e2015626~ (2020)
52. Saillard C, "Predicting survival after hepatocellular carcinoma resection using deep learning on histological slides", Hepatology, 72, pp.2000~2013 (2020)
53. Nam JY, "Novel model to predict HCC recurrence after liver transplantation obtained using deep learning: a multicenter study", Cancers(Basel), 12, pp.2791~ (2020)
54. Cho JY, "Thrombosis confined to the portal vein is not a contraindication for living donor liver transplantation", World J Surg, 32, pp.1731~1737 (2008)
55. Trotter JF, "Liver transplantation around the world", Liver Transpl, 22, pp.1059~1061 (2016)
56. Samoylova ML, "Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation", Liver Transpl, 20, pp.937~944 (2014)
57. Bozorgzadeh A, "Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis", Liver Transpl, 13, pp.807~813 (2007)
58. Wu TJ, "Liver transplantation in patients with hepatitis B virus-related hepatocellular carcinoma : the influence of viral characteristics on clinical outcome", Ann Surg Oncol, 20, pp.3582~3590 (2013)
59. Tse CS, "Direct-acting antiviral therapy in liver transplant patients with hepatocellular carcinoma and hepatitis C", Transplant Direct, 7, pp.e635~ (2020)
60. Gorgen A, "The impact of direct-acting antivirals on overall mortality and tumoral recurrence in patients with hepatocellular carcinoma listed for liver transplantation : an international multicenter study", Transplantation, 104, pp.2087~2096 (2020)
61. Malinchoc M, "A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts", Hepatology, 31, pp.864~871 (2000)
62. Bernardi M, "The MELD score in patients awaiting liver transplant : strengths and weaknesses", J Hepatol, 54, pp.1297~1306 (2011)
63. Kim KM, "Child-Pugh, MELD, MELD-Na, and ALBI scores: which liver function models best predicts prognosis for HCC patient with ascites?", Scand J Gastroenterol, 55, pp.951~957 (2020)
64. Guerrini GP, "Value of HCC-MELD score in patients with hepatocellular carcinoma undergoing liver transplantation", Prog Transplant, 28, pp.63~69 (2018)
65. Abdel-Wahab R, "Impact of integrating insulin-like growth factor 1 levels into model for end-stage liver disease score for survival prediction in hepatocellular carcinoma patients", Oncology, 98, pp.836~846 (2020)
66. Cho CW, "Clinical impact of anatomical resection on long-term outcomes after hepatectomy for primary solitary hepatocellular carcinoma with or without preoperative positron emission tomography positivity", Ann Transl Med, 8, pp.1377~ (2020)
67. Lee SD, "Clinical impact of 18ffluorodeoxyglucose positron emission tomography", computed tomography in living donor liver transplantation for advanced hepatocellular carcinoma, 2015, pp.99, 2142~2149
68. Takada Y, "Significance of preoperative fluorodeoxyglucose-positron emission tomography in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients : a Japanese multicenter study", J Hepatobiliary Pancreat Sci, 24, pp.49~57 (2017)
69. Pavel MC, "Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation : future directions", World J Gastroenterol, 24, pp.3626~3636 (2018)
70. Liese J, "A possible role of microRNAs as predictive markers for the recurrence of hepatocellular carcinoma after liver transplantation", Transpl Int, 29, pp.369~380 (2016)
71. Barry CT, "Micro RNA expression profiles as adjunctive data to assess the risk of hepatocellular carcinoma recurrence after liver transplantation", Am J Transplant, 12, pp.428~437 (2012)
72. Kim J, "Detection of hepatocellular carcinoma in contrast-enhanced magnetic resonance imaging using deep learning classifier : a multi-center retrospective study", Sci Rep, 10, pp.9458~ (2020)
73. Liu SC, "Predicting microvascular invasion in hepatocellular carcinoma : a deep learning model validated across hospitals", Cancer Imaging, 21, pp.56~ (2021)
74. Luckshi Rajendran, "The management of post-transplantation recurrence of hepatocellular carcinoma", Clinical and Molecular Hepatology, 28(1), pp.1~16 (2022), 대한간학회[DOI]
75. Vivarelli M, "Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors : reassessment of risk factors for tumor recurrence", Ann Surg, 248, pp.857~862 (2008)
76. Koehl GE, "Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice", Transplantation, 77, pp.1319~1326 (2004)
77. Schnitzbauer AA, "mTOR inhibition is most beneficial after liver transplantation for hepatocellular carcinoma in patients with active tumors", Ann Surg, 272, pp.855~862 (2020)

관련 논문AI추천